Methylene Blue Modulates Huntingtin Aggregation Intermediates and Is Protective in Huntington's Disease Models
Open Access
- 8 August 2012
- journal article
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 32 (32), 11109-11119
- https://doi.org/10.1523/jneurosci.0895-12.2012
Abstract
Huntington's disease (HD) is a devastating neurodegenerative disorder with no disease-modifying treatments available. The disease is caused by expansion of a CAG trinucleotide repeat and manifests with progressive motor abnormalities, psychiatric symptoms, and cognitive decline. Expression of an expanded polyglutamine repeat within the Huntingtin (Htt) protein impacts numerous cellular processes, including protein folding and clearance. A hallmark of the disease is the progressive formation of inclusions that represent the culmination of a complex aggregation process. Methylene blue (MB), has been shown to modulate aggregation of amyloidogenic disease proteins. We investigated whether MB could impact mutant Htt-mediated aggregation and neurotoxicity. MB inhibited recombinant protein aggregation in vitro, even when added to preformed oligomers and fibrils. MB also decreased oligomer number and size and decreased accumulation of insoluble mutant Htt in cells. In functional assays, MB increased survival of primary cortical neurons transduced with mutant Htt, reduced neurodegeneration and aggregation in a Drosophila melanogaster model of HD, and reduced disease phenotypes in R6/2 HD modeled mice. Furthermore, MB treatment also promoted an increase in levels of BDNF RNA and protein in vivo. Thus, MB, which is well tolerated and used in humans, has therapeutic potential for HD.Keywords
This publication has 59 references indexed in Scilit:
- Identifying polyglutamine protein species in situ that best predict neurodegenerationNature Chemical Biology, 2011
- Inhibition of Hsp70 by Methylene Blue Affects Signaling Protein Function and Ubiquitination and Modulates Polyglutamine Protein DegradationPublished by Elsevier BV ,2010
- Mutant Huntingtin Fragments Form Oligomers in a Polyglutamine Length-dependent Manner in Vitro and in VivoJournal of Biological Chemistry, 2010
- Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease miceNeuroscience, 2008
- The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse modelExperimental Neurology, 2008
- A small-molecule therapeutic lead for Huntington's disease: Preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouseProceedings of the National Academy of Sciences of the United States of America, 2007
- The brain metabolic enhancer methylene blue improves discrimination learning in ratsPharmacology Biochemistry and Behavior, 2007
- Chaperonin TRiC Promotes the Assembly of polyQ Expansion Proteins into Nontoxic OligomersMolecular Cell, 2006
- Automated microscope system for determining factors that predict neuronal fateProceedings of the National Academy of Sciences of the United States of America, 2005
- Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal deathNature, 2004